Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Closes $4.4M Financing Round, $30M Debt Facility

NEW YORK (GenomeWeb) – Nanosphere has closed its direct offering of $4.4 million Series A convertible preferred stock and has secured a $30 million debt facility with NSPH Funding, an affiliate of Life Sciences Alternative Funding and SWK Funding.

The firm had announced earlier this week, in conjunction with its first quarter results, that it had commenced the preferred stock offering. Nanosphere issued 1,168,659 shares of common stock at a conversion price of $3.765 per share and warrants to purchase an equal amount of shares of common stock. The warrants have an exercise price of $3.65 per share and are exercisable for five years, commencing six months after the closing date of the offering. 

Nanosphere also issued warrants to purchase 70,120 shares at an exercise price of $4.45 per share to H.C. Wainwright, which acted as exclusive placement agent.

The firm said net proceeds from the offering were approximately $4.0 million, which it intends to use for general corporate purposes and working capital.

Nanosphere also said it immediately drew down $20 million of the new $30 million debt facility. At the same time, the firm closed its existing debt facility with Silicon Valley Bank and Oxford Finance, repaying approximately $8.9 million. Nanosphere said it intends to use the remaining proceeds for general corporate purposes and working capital, including development of its next-generation Verigene pathogen detection platform.

As of March 31, Nanosphere held $14.2 million in cash and cash equivalents.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.